Lennox–Gastaut Syndrome (LGS) Market

Jan 05, 2021

10 likes | 18 Views

Lennoxu2013Gastaut Syndrome (LGS) is a severe pediatric epilepsy syndrome characterized by the presence of multiple pharmaco-resistant seizure types, including tonic, atypical absences, and tonic or atonic drop attacks, and the presence of electroencephalographic abnormalities. As per the Delveinsight, in 2017, the market size of Lennoxu2013Gastaut Syndrome (LGS) in the 7MM was 136.6 Million. The total prevalent population of Lennoxu2013Gastaut Syndrome (LGS) in the 7 MM was 111,798 in 2017. The prevalent population of LGS in the United States was 47,256. Promising emerging therapies, increase in R&D and government initiatives and funding are some of the key drivers for Lennoxu2013Gastaut Syndrome (LGS) Market. Some of the key companies in the Lennoxu2013Gastaut Syndrome (LGS) Market include Eisai, Zogenix, Takeda, Ovid, and many others. Source: Lennoxu2013Gastaut Syndrome (LGS) Market

DelveInsight

Download Presentation

Lennox–Gastaut Syndrome (LGS) Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D